Abstract: The pharmaceutical, vaginal applicable preparation is characterized in that it contains, homogeneously sub-divided, at least one in water soluble poly-vinyl alcohol, at least one component A, selected from the group consisting of wetting agents, non-ionic surface active agents and dispersing agents, as well as at least one active component B for the local treatment of sexually transmissible or transmitted, respectively, diseases, and/or for vaginal infections, and occasionally one or more auxiliary agent(s), and in that it is in the form of a film having a thickness of the layer of from 0.05 to 0.5 mm, especially from 0.06 to 0.2 mm, preferably from 0.07 to 0.15 mm.

Abstract: Methods and compositions are provided for the treatment and repair of defects or lesions in the cartilage of humans and other animals. The defect or lesion in the cartilage may be first treated with an enzyme to remove proteoglycans from the defect area. To induce cartilage formation, the defect is filled or otherwise dressed with a biodegradable matrix having pores sufficiently large to allow repair cells to populate the matrix. The matrix filling the defect contains a proliferation agent at a concentration sufficient to stimulate proliferation of repair cells and a transforming factor in an appropriate delivery system to release the transforming factor at a concentration sufficient to transform repair cells in the matrix and defect area into cartilage-producing chondrocytes. The matrix may also contain a chemotactic agent to attract repair cells. The entire treatment may be carried out in a single arthroscopic or open surgical procedure.

Abstract: When a transdermal therapeutic composition which contains a pharmaceutically effective ingredient, a water-soluble absorption enhancer, a fat-soluble absorption enhancer and a super water-absorbent resin is applied to the skin of mammals, release of the pharmaceutically effective ingredient and the absorption enhancers is controlled and the pharmacological action lasts for a long period of time.

Abstract: The present invention relates to a process for preparing a bioadhesive sustained-release pharmaceutical dosage form, characterized in that:a) at least a part of the active principles is mixed with a quantity of natural proteins representing at least 50% by weight of active principle, and with 0.5 to 10% of a hydrophilic polymer,b) the mixture obtained at the end of step a is subjected to granulation in the presence of approximately 60.degree. strength alcohol, followed by drying to bring it to a moisture content of approximately 3%.c) the granules thereby obtained, after sizing, are mixed with standard formulation excipients, especially ballast materials, lubricants, flavorings and sweeteners,d) the mixture obtained at the end of step c, is subjected to tabletting for the purpose of obtaining bioadhesive sustained-release tablets.It also relates to a pharmaceutical dosage form displaying long-lasting properties of adhesiveness to the mucosae.

Abstract: A method and system for mucosally administering a macromolecular drug to mucosa of the oral cavity is shown. The system comprises an inner drug/enhancer/polymer layer having one surface adapted to contact and adhere to the mucosal tissue of the oral cavity and an opposing surface in contact with and adhering to an overlying inert layer. The inner layer contains from about two to sixty percent by weight of a bile salt enhancer, five to sixty five percent by weight of a hydrophilic polymer which is water soluble or swellable and an effective amount of a macromolecular drug having a molecular weight of at least 500 daltons. Polysaccharides, polypeptides and proteins are preferred forms of macromolecular drugs. The bile salt enhancer facilitates the delivery of macromolecules such as low molecular weight heparin and calcitonin. The polymer serves as a plasticizer to prevent the crystallization and/or aggregation of such macromolecular drugs. Hydroxypropyl cellulose is a particularly suitable polymer.

Abstract: A polymeric controlled delivery system is provided for use in treating periodontal disease. The delivery system in a variety of forms is placed directly in the infected gingival tissue where the chemotherapeutic agent is slowly released into the tissue and into the infected periodontal pocket by means of the gingival crevicular fluid originating in the gingival tissue.

Abstract: Controlled release pharmaceutical preparations are prepared by homogenizing an organic or inorganic pharmaceutical active substance such as an opium alkaloid or its salts, an opium antagonist or its salts, an aliphatic or aromatic amine derivative or its salts, a phenolate type medicament, or Zn, Fe, Mg, K, Na salts, a fatty acid or its salt necessary to achieve a continuous phase transfer and an ethylene vinyl acetate copolymer and formulating the resulting homogeneous mixture bya) direct compressing orb) admixing with a solvent orc) using a second, auxiliary polymer.The preparations are suitable for oral or rectal administration or for tissue implantation.

Abstract: A shaped piece of swollen demineralized bone which can also be plasticized is provided for use in surgical bone repair.

Abstract: A salt of an uncrosslinked copolymer of a monoethylenically unsaturated mono- or dicarboxylic acid and an alkyl ester of acrylic or methacrylic acid is suitable as a pressure-sensitive skin adhesive for plasters, for transdermal pharmaceutical forms, or for fastening bandages, which is permanently flexible and can be washed off with water, for which the proportion of carboxylic acid has to be sufficient to make the copolymer water-soluble in the salt form.

Abstract: Methods and compositions are provided for coating a substrate with a strongly adherent hydroxyapatite coating, which allows for ingrowth of natural bone and strong bonding between the coating and the substrate. The procedure provides for repetitive coatings at varying concentrations of coating forming reagents, where the highest concentration is used initially. The coating has particular application for prostheses, where porous areas of the prostheses are completely coated with a thin sturdy coating of hydroxyapatite.

Abstract: A cosmetic product is provided that stores a cosmetic composition in a capsule having a spheroidal body with hollow chamber forming a major portion of the capsule, a tab forming a minor portion of the capsule, and a neck section connecting the tab with the spheroidal body. At least two wings are positioned along opposite sides of the spheroidal body perpendicularly extending outward therefrom. Upon twisting, the neck can be broken to allow release of cosmetic composition from within the chamber.

Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

Abstract: This invention relates to compositions/devices and methods for treating diseases of the oral cavity in humans and lower animals using polylactide/glycolide compositions/devices also containing triacetin for releasing drugs in the oral cavity.

Abstract: Preparation for preventing or combating complications in diabetes, characterized in that it comprises:(a) insulin or a salt or complex thereof, and(b) a peptide of the general formula I:H-L-Met(X)-L-Glu-L-His-L-Phe-D-Lys-L-Phe-Yor a salt or a N-acyl derivative thereof, whereinMet(X) represents the amino acid radical Met, Met(O) or Met(O.sub.2),Y represents the group Gly-Z or Z, andZ represents the hydroxyl group, an esterified hydroxyl group or a substituted or unsubstituted amino group.

Abstract: Methods and compositions are provided for the treatment and repair of defects or lesions in the cartilage of humans and other animals. The defect or lesion in the cartilage may be first treated with an enzyme to remove proteoglycans from the defect area. To induce cartilage formation, the defect is filled or otherwise dressed with a biodegradable matrix having pores sufficiently large to allow repair cells to populate the matrix. The matrix filling the defect contains a proliferation agent at a concentration sufficient to stimulate proliferation of repair cells and a transforming factor in an appropriate delivery system to release the transforming factor at a concentration sufficient to transform repair cells in the matrix and defect area into cartilage-producing chondrocytes. The matrix may also contain a chemotactic agent to attract repair cells. The entire treatment may be carried out in a single arthroscopic or open surgical procedure.

Abstract: Lightly crosslinked polymers, preferably ones prepared by suspension or emulsion polymerizing at least about 90% by weight of a carboxyl-containing monoethylenically unsaturated monomer such as acrylic acid with from about 0.1% to about 5% by weight of a polyfunctional, and preferably difunctional, crosslinking agent such as divinyl glycol (3,4-dihydroxy-1,5-hexadiene), having a particle size of not more than about 50 .mu.m in equivalent spherical diameter, when formulated with an ophthalmic medicament, e.g., fluorometholone, into suspensions in aqueous medium in which the amount of polymer ranges from about 0.1% to about 6.5% by weight, based on the total weight of the aqueous suspension, the pH is from about 3.0 to about 6.

Abstract: A topical, aqueous ophthalmic gel suspension for dry eye is administrable to the eye in drop form, remains as a gel in the eye for a prolonged time, and releases water and one or more ophthalmic demulcents or vasoconstrictors. It comprises water and from 0.1% to 6.5% by weight of lightly cross-linked carboxyl-containing polymer having a particle size of not more than about 50 .mu.m in equivalent spherical diameter. The suspension is at a pH of from 6.6 to 8.0, has an osmolality of from 50 to 400 mOsM, and a viscosity of from about 500 to about 4,000 centipoise (0.5 to 4 Pa.s).

Abstract: A method for preventing the sickling of sickle cells in a patient having sickle cell disease, the method which comprises administering to the patient a therapeutically effective amount of a compound having the formula: ##STR1## wherein X.sup.- is selected from the group consisting of iodide, chloride, bromide, hydroxyl, nitrite, phosphate and acetate.

Abstract: Methods and compositions are provided for coating a substrate with a strongly adherent hydroxyapatite coating, which allows for ingrowth of natural bone and strong bonding between the coating and the substrate. The procedure provides for repetitive coatings at varying concentrations of coating forming reagents, where the highest concentration is used initially. The coating has particular application for prostheses, where porous areas of the prostheses are completely coated with a thin sturdy coating of hydroxyapatite.

Abstract: Disclosed is a makeup material for human use containing a shape memory polymer shaped into fine spheres. The shape memory polymer used is a polyurethane that is obtained by polymerizing with the prepolymer method a composition of a bifunctional diisocyanate, a bifunctional polyol, and a bifunctional chain extender with active hydrogen groups in the mole ratio of diisocyanate:polyol:chain extender=2.00-1.10:1.00:1.00-0.10. The polyurethane is preferred to have approximately equal amounts of NCO groups and OH groups at its ends, and a glass transition point above the human body temperature, and a crystallinity value between 3 to 50 wt %.

Abstract: A composition comprising a polymer having dispersed therethrough a prostacyclin derivative selected from the group consisting of compounds of formula (I): ##STR1## (in which R.sup.1 represents hydrogen or lower alkyl, R.sup.2 represents a C.sub.3 -C.sub.12 alkyl group or a C.sub.3 -C.sub.12 alkenyl group; and n is an integer from 1 to 5; and pharmaceutically acceptable salts thereof) can be used to make a medical appliance from which the prostaglandin, having antithrombotic properties, will be released gradually and in a controlled way.

Abstract: A drug preparation applicable to the oral mucosa is disclosed, comprising a soft adhesive film containing a systemic drug, the adhesive film comprising a homogeneous mixture comprising a vinyl acetate homopolymer, an acrylic acid polymer, and a cellulose derivative capable of being dissolved in or swollen with water and a lower alcohol. The drug preparation is less causative of an adverse feeling in the oral cavity on use, excellent in shape retention on water absorption, and adhesive to the oral mucosa for an extended period of time, thereby achieving a stable administration of a systemic drug for a long time.

Abstract: New polysaccharide esters are disclosed, and more precisely esters of acidic polysaccharides chosen from the group formed by carboxymethylcellulose, carboxymethyl starch and carboxymethylchitin. These new esters and some esters of the type already known are useful as medicaments, for the manufacture of pharmaceutical and cosmetic preparations, in the field of biodegradable plastic materials and, therefore, for the manufacture of medical, surgical and sanitary articles, as well as numerous other industrial sectors in the place of acidic polysaccharides now in common use.

Abstract: A unique method (10) for preparing protein-impacted grafts (22) wherein an untreated graft (22) is impacted and impregnated with a protein solution, ideally a collagen suspension (14) utilizing a dynamic flow soaking process (24). After soaking in the dynamic flow (24), the collagen-impacted graft is thermally and chemically fixed (26). Following a water wash (30) and glycine wash (34), the graft (22) is softened with a plastification procedure (36), after which it is air dried (38) and placed in a package and sterilized. With the method of the present invention, storable, surgically-ready collagen-impacted grafts can be reliably and rapidly prepared with a high degree of control and uniformity of characteristics in each graft than has heretofore been possible.

Abstract: Implant preparations capable of sustained action when inserted are comprised of powder of a natural lipoidal substance in thorough admixture with bioactive macromolecule, followed by compression under pressure into a disc or rod that can be broken and used in small pieces as well.

Abstract: A method for preventing the sickling of sickle cells in a patient having sickle cell disease, the method which comprises administering to the patient a therapeutically effective amount of a compound having the formula: ##STR1## wherein X.sup.- is selected from the group consisting of iodide, chloride, bromide, hydroxyl, nitrite, phosphate and acetate.

Abstract: A cyclic peptide designated FR115224, administered parenterally in a cyclodextrin carrier, which exhibits antiallergic activity.

Abstract: A method for preventing adhesion between vital tissues includes the step of placing between the tissues a material made up of biodegradable derivatives of chitin which are soluble in aqueous solutions containing dilute acids such as acetic acid. This material has the advantage of requiring no reoperation for its removal since it would be degraded and absorbed after completing its function in vivo. These materials may be in the form of a visco-elastic fluid, a gel, a film or a membrane.

Abstract: A leach resistant composition includes a quaternary ammonium complex of heparin and a silicone. A method for applying a coating of the composition to a surface of a medical article is within the purview of the present invention. Medical articles having surfaces which are both lubricious and antithrombogenic, are produced in accordance with the method hereof.

Abstract: A nasal administration powder composition containing a physiologically active peptide as an active ingredient can be efficiently absorbed through nasal mucosa by the addition of a water-soluble organic acid as an absorption promoter. This composition may further contain a diluent. The water-soluble organic acid used as absorption promoter includes, for example, at least one of succinic acid, tartaric acid, citric acid, fumaric acid, maleic acid, malonic acid, glutaric acid, adipic acid, malic acid, L-glutamic acid, L-aspartic acid, gluconic acid and glucuronic acid.

Abstract: A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.

Abstract: Improvement in healing of wounds of the corneal stroma is obtained by placing into the wounds a corneal mortar composition comprising an extracellular matrix material and an ophthalmologically compatible carrier material, the composition having a sufficiently high viscosity to retain it within the wound under wound-healing conditions.

Abstract: A pharmaceutical composition for treating periodontal diseases which comprises one or more of therapeutically active ingredients admixed with a polymer capable of dissolving in an aqueous medium of pH 4.0 or higher.

Abstract: Improvement in healing of wounds of the corneal stroma is obtained by placing into the wounds a corneal mortar composition comprising an extracellular matrix material and an ophthalmologically compatible carrier material, the composition having a sufficiently high viscosity to retain it within the wound under wound-healing conditions.

Abstract: Wound healing dressings are prepared by flocculating fibronectin, a biologically active fragment or an analog thereof to produce a water-swellable gel. The gels, in the form of sheets, strips, wedges, strands or I-shaped cross-sections, are especially useful in promoting the healing of corneal, scleral dermal, incisional wounds or lesions. They can be used to enhance the results obtained in keratorefractive surgeries and the healing scleral incision for intraocular surgery.

Abstract: Healing of injured avascular tissue is promoted by applying angiogenic factor in proximity to the injured tissue.

Abstract: A composition and formulation for use in covering and healing of wounds to the body, the formulation consisting of a mixture of a tissue compatible, water-based acrylic adhesive and collagen. The formulation comprises from between about 0.1% and 10% of collagen (dry basis), with the adhesive component preferably containing about 50% solids, balance water.

Abstract: Novel film-forming gel compositions are described comprising from 10-40% by weight of a water dissipatable polymer, from 10 to 40% by weight of humectants and 20-60% by weight of water. The gel compositions may also be in the form of an emulsion comprising from 15-30% by weight of a water dissipatable polymer, from 15 to 35% by weight of humectants, up to 40% by weight of emollients, from 15 to 35% by weight water and a small amount of emulsifier. Additionally the gels of the present invention may contain optional agents such as, for example, coloring agents, pigments, preservatives, medical agents, cosmetic agents or agents to modify the refractive index of the gel.

Abstract: Delivery systems containing at least one aminopolysaccharide derivative are provided for the delivery of pharmaceutical or therapeutic actives to a desired topical or mucous membrane site in a subject, and wherein upon delivery, the systems provides a biocompatible, substantive, gas permeable, film from which actives are available at the designated site.

Abstract: Heterogeneous acid decrystallization of aminopolysaccharides, especially chitosen, using diluent, organic acid and water, provides novel salts and covalent derivatives useful in diverse applications including biomedicine, personal care and fluid separation.

Abstract: Pullulan forms an association complex with PEG in a hydrous system. The assocation complex, as well as its pullulan and PEG components, exerts a decreased solubility in water. The association reduces or even eliminates the excessively high water-solubility, threading and stickiness of pullulan so that this extends the uses of pullulan and PEG such as those in gradually disintegrable- and sustained release-shaped articles for consumer's products, toiletries, cosmetics, pharmaceuticals and feeds.

Abstract: Disclosed are wax based cosmetic stick compositions comprising: from about 10% to about 50% of a wax type solidifying agent; and from about 5% to about 90% of a polyalphaolefin. These compositions preferably comprise from about 1.0% to about 40% of an active component, such as a sunscreen agent, analgesic, moisturizing and antiperspirant or a deodorant active.

Abstract: The present disclosure relates to an external analgesic solid stick composition for the topical administration of active analgesic agents. The compositions are dimensionally stable solid compositions comprising an external analgesic agent incorporated into a non-reactive hydrophobic wax matrix.

Abstract: A chewing material or items constructed of latex material. In one embodiment of the invention, the latex chewing material is constructed to simulate the size and shape of a stick of conventional chewing gum. The latex material will not deteriorate when being chewed and while not intended to be ingested, it is constructed of non-toxic material and is not harmful if swallowed. The latex chewing material will not stick to any surface or any other item. The material is not water soluble and is sugar free and salt free. Use of the latex chewing material or item will assist in keeping the teeth clean, promote healthy conditions of the teeth and gum by massaging the gums and providing exercise normally associated with mastication. In addition, the use of the latex chewing material will enhance the overall health and hygiene of the oral cavity by stimulating saliva secretions thereby decreasing the potential for bad breath.

Abstract: A sheet-shaped adhesive preparation comprising an adhesive layer containing as essential components a carboxyvinyl polymer, a water-insoluble methacrylic copolymer, a polyhydric alcohol and a pharmaceutically active agent, and a water-impermeable and water-insoluble carrier layer containing as essential components a pharmaceutically acceptable water-insoluble, film-forming high molecular weight compound and a plasticizer, which can adhere within the oral cavity for a longer period of time and can release the active agent and hence is useful as a sustained release preparation for the oral cavity.

Abstract: An antigen delivery system utilizing a biodegradable polymer with good mechanical properties in combination with a material stimulating the immune system. The material having adjuvant activity may be polymer degradation products or an adjuvant which is contained within or bound to the polymer. In one embodiment, the polymer is formed from tyrosine dipeptides. Poly(CTTH-iminocarbonate) is a preferred tyrosine dipeptide polymer for constructing implantable delivery systems for antigenic material. The polymer is not an adjuvant in itself but degrades into products which stimulate the immune system. The tyrosine dipeptide can also be used as a conventional adjuvant.

Abstract: 5-Amino or substituted amino 1,2,3-triazoles are disclosed as a new class of antiproliferative agents useful in the treating and managing of psoriasis, inflammatory bowel syndrome, cutaneous leishmanilisis and certain types of cancer.

Abstract: Compositions and methods are disclosed for the treatment of obesity, depression, drug abuse, and narcolepsy. The compositions comprise a norepinephrine precursor such as L-tyrosine or L-phenylalanine in combination with a norepinephrine re-uptake inhibitor such as desipramine. In another embodiment of the invention, the compositions further comprise enzymatic cofactors for the biosynthesis of norepinephrine.

Abstract: An active agent-containing laminated material and the method for producing the same, in which an impermeable film is temporarily adhered to at least one side surface of an active agent-containing film and impermeable film can be peeled off and readhered repeatedly. The laminated material is prepared by directly laminating a molten web of active agent-containing polyolefin composition with an impermeable film at and pressing them together, said active agent-containing polyolefin composition comprising: (A) 10 to 100 parts by weigh to carboxyl group-containing ethylene based copolymer of at least 7% by weight in the content of carboxyl group-containing monomer; (B) 90 parts by weight or less of low density polyethylene having a melt index of at least 30 g/10 min.; and (C) at least 0.005 parts by weight of an active agent or agents relative to 100 parts by weight of said polymers (A) plus (B).

Abstract: The present invention pertains to a preparation for diagnosing the transport function of the fallopian tube and to a method for making such a preparation.The diagnostic preparation for investigation of the transport function of female fallopian tube, comprises a suspension of a biocompatible, biodegradable, and, if desired, labelled particles, in a vehicle commonly used for parenteral applications wherein the particles have a spherical shape with diameters in the region 10 to 600 um, which are formed from a soft hydrophilic gel based on a polymer selected from the group comprising additionally crosslinked water-soluble nontoxic and biodegradable inert polysaccharides and physiologically inert water-soluble and biodegradable poly(amino acids), polypeptides, and their derivatives, which may contain physiologically active substances.